New dimensions: exploring recent data and measure in IBD

Learning objectives:

After this meeting, participants should be able to:

• Describe recent developments in UC, including: drugs targeting the IL-12/23 pathways; new targets, such as histological healing; and outcomes, such as better sustained steroid-free remission  
• Describe how effective we are in predicting outcomes in UC
• Recognize how recent data can impact clinical practice

Speakers:

Matthieu Allez (Scientific Committee), Alessandro Armuzzi, and Séverine Vermeire (Scientific Committee)